Breast cancer is the most common cancer among women. Thankfully, genetic data collection has revolutionized its management and supported strategies to lower its mortality rate. For example, researchers looked into gene mutations BRCA1 and BRCA2, revolutionizing breast cancer treatment in various ways: (1) Scanning for these mutations helps identify those hereditarily at high risk, allowing for proactive risk management strategies including risk-reducing surgeries like mastectomy and oophorectomy to significantly lower the risk of developing new or recurrent cancers; (2) BRCA testing, both for inherited mutations and somatic mutations within the tumor, allows for the identification of patients who may benefit from specific therapies, enabling personalized approaches based on a patient's genetic makeup; (3) Conversely, knowing a patient has a BRCA mutation disqualifies certain treatments like platinum-based chemotherapy, which BRCA-mutated breast cancers may be more sensitive to, also enabling personalized treatments. Understanding the impact of these mutated genes, such as the stated above, has led to the development of targeted therapies like PARP inhibitors, which are particularly effective against cancers with BRCA mutations. These inhibitors work by interfering with a cancer cell's ability to repair damaged DNA, leading to the death of the cancer cell. BRCA1 and BRCA2 are tumor suppressor genes involved in DNA repair, and mutations in these genes can make cancer cells more vulnerable to PARP inhibitors, making it a near-perfect treatment for breast cancer stemmed from BRCA mutations. To continue to discover amazing treatments like PARP inhibitors, scientists need research material. To aid them in their revolutionary breakthroughs, you can anonymously share your data with 46forALL.